Guido BaechlerPresident and Chief Executive Officer
Guido Baechler has served as President and Chief Executive Officer of Singulex since 2013, bringing with him over two decades of experience working with emerging technologies in the life sciences and diagnostics industries. Guido joined Singulex in 2008, serving first as Vice President of Diagnostics and then as Senior Vice President of Operations. Previously, Guido worked at Roche in both the U.S. and Switzerland. He held executive and leadership positions at both Roche Diagnostics and Roche Molecular Diagnostics and gained managerial and functional expertise in research, development and marketing.
Guido holds a B.S. in Electrical Engineering from Fachhochschule Brugg-Windisch in Switzerland. He has completed a series of executive finance and management classes at the London School of Business and the Haas School of Business, University of California, Berkeley.
David Ian BellChief Innovation Officer, Grifols
David Ian Bell is the Chief Innovation Officer for Grifols S.A. Additionally, he is the President and Chief Executive Officer of Grifols Innovation and New Technology Limited (GIANT). He also serves as General Counsel with responsibility for, among other things, mergers and acquisitions and new business development. Mr. Bell serves on Grifols Corporate, Bioscience, Diagnostic and Hospital Executive Committees and is on the Board of Directors of numerous Grifols’ portfolio companies including Alkahest, Aradigm, Singulex, and Araclon.
Prior to joining Grifols in 2003, Mr. Bell served as General Counsel and Vice President of Alpha Therapeutic Corporation following more than 20 years as a corporate lawyer specializing in healthcare, pharmaceutical and biotechnology regulation and liability. Mr. Bell attended the University of California, Irvine focusing on Psychobiology (Neuroscience), Southwestern University School of Law and a postgraduate program at Harvard Law School.
Heiner Dreismann, Ph.D.Lead Director
Heiner Dreismann, Ph.D. has been a member of our board of directors since June of 2007 and has over 26 years of experience in biotech and healthcare companies. Since May of 2008, Dr. Dreismann has served as Interim Chief Executive Officer of GeneNews Limited, a public diagnostics company. From 2001 until 2006, Dr. Dreismann served as President and Chief Executive Officer of Roche Molecular Systems, Inc., a division of Hoffmann-La Roche Ltd., or Roche, focused on clinical molecular diagnostics.
Before serving in these roles, he held various management positions in Roche, among them Head of Integration Office Diagnostics and Head of Global Business Development for Roche Diagnostics. Dr. Dreismann currently serves on the boards of directors of Ignyta, Inc., Myriad Genetics, Inc., Med BioGene Inc. and GeneNews Ltd., each a public company in the life sciences or healthcare diagnostics sectors. Dr. Dreismann received his M.A. in Biology and his Ph.D. in Microbiology / Molecular Biology both from Westfaelische Wilhelms University (The University of Münster) in Germany. Dr. Dreismann brings to our board of directors significant expertise in the biotech and healthcare sectors from both his advanced degree and from previous executive leadership positions. In addition, Dr. Dreismann’s experience as a Director of public life sciences companies provides the board of directors with valuable insights to assist in achieving our goals.
Carl L. Gordon, Ph.D., CFAGeneral Partner, OrbiMed and Co-Head, Private Equity
Carl Gordon, Ph.D., CFA has been a member of our board of directors since June of 2007. Dr. Gordon co-founded OrbiMed Advisors LLC, or OrbiMed, where he serves as a General Partner and Co-Head of Private Equity. He is experienced in both private equity and small-capitalization public equity investments. Prior to his experience at OrbiMed, Dr. Gordon was a senior biotechnology analyst at Mehta and Isaly, a pharmaceutical consulting firm and predecessor to OrbiMed, from 1995 to 1997.
From 1993 to 1995, Dr. Gordon was a fellow at The Rockefeller University. He received his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and a bachelor’s degree from Harvard College.
From August 2009 until June 2012, Dr. Gordon also served on the board of directors of Complete Genomics, Inc., a life sciences company. As a venture capitalist focused on life science companies who sits on numerous boards, Dr. Gordon provides financial and operational expertise regarding our industry. In addition, Dr. Gordon provides substantial expertise in the particularly relevant scientific field of molecular biology, and his financial credentials are valuable toward his service on our audit committee.
Stephen L. Rose, CPA, CMADirector, Fisk Ventures, LLC
Steve Rose, CPA, CMA, has been a member of our board of directors since September, 2004. Mr. Rose, who has over 17 years of experience in venture investing, is Managing Director of Fisk Ventures, LLC, the venture investment company for H. Fisk Johnson, Ph.D., Chairman of the Board, Chairman and Chief Executive Officer of S.C. Johnson and Son Inc., or S.C. Johnson. In this capacity, Mr. Rose serves on the boards of several early stage technology-based companies. Mr. Rose previously held several positions with S.C. Johnson in both the United States and in Canada, including positions in strategic planning, new business and new product development, and financial and business management.
Mr. Rose has an Honors Bachelor of Commerce from McMaster University, and is also a Certified Management Accountant. As a venture capitalist with experience on the boards of several emerging companies, Mr. Rose provides the Singulex Board of Directors with insightful and relevant expertise in both finance and operations. In addition, his financial credentials and experience are of significant value in his service on our governance committee.
Fred K. VogtPresident, FKV Enterprises, LLC
Fred Vogt has been a member of our board of directors since our incorporation in 2002. Mr. Vogt has 28 years of operations and manufacturing experience in the pharmaceutical industry, and he currently provides consulting services to senior management executives through FKV Enterprises LLC. From 1997 until 2000, Mr. Vogt served as a Senior Vice President of Specialty Chemicals at Tetra Technologies Inc., a chemical manufacturer.
Prior to this experience, he worked for 25 years for Mallinckrodt, Inc., a chemical and pharmaceutical company, in a variety of manufacturing and business positions. Mr. Vogt has a bachelor’s degree in Chemical Engineering, a master’s degree in Engineering Administration and Honorary Professional Chemical Engineering degree from the University of Missouri at Rolla.